Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.30.

CGTX has been the subject of several research analyst reports. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $1.00 to $1.50 in a report on Thursday, December 19th. HC Wainwright raised their target price on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Finally, Chardan Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a report on Thursday, December 19th.

Cognition Therapeutics Trading Up 9.5 %

Cognition Therapeutics stock opened at $0.84 on Tuesday. The firm has a market capitalization of $34.90 million, a P/E ratio of -0.87 and a beta of 1.26. The business has a 50-day moving average of $0.50 and a 200-day moving average of $0.88. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CGTX. Virtu Financial LLC acquired a new position in Cognition Therapeutics during the third quarter worth $27,000. Sigma Planning Corp increased its holdings in shares of Cognition Therapeutics by 14.6% in the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the period. Finally, CM Management LLC lifted its stake in shares of Cognition Therapeutics by 14.3% during the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after buying an additional 25,000 shares during the last quarter. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.